CHINA - 2024/09/21: In this photo illustration, a Pfizer logo is displayed on the screen of a ... [+] smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis, slightly above the consensus estimates of $14.9 billion and $0.62, respectively ...

The company's problems are no longer deniable. Pfizer's (PFE -0.66%) burgeoning tiff with activist investor group Starboard Value looks like it's escalating. Since the activist took a $1 billion stake in the drug developer, it's been an open question as to what it wants changed and how it proposes to do so. Now, after a presentation at the 13D Monitor Active-Passive Investor Summit by Starboard's CEO Jeffrey Smith on Oct. 22, there's a lot less ambiguity. In particular, Smith had seven simple and brutal wor ...

Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.64 per share in its upcoming report, which indicates a year-over-year increase of 476.5%. Revenues are expected to be $15.19 billion, up 14.8% from the year-ago quarter.The current level reflects an upward revision of 3.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company an ...

I initiated coverage on Pfizer (NYSE: PFE ) stock with a "Buy" rating, stating that the company's low valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector. In early May, IHe leads the investing group Beyond the Wall Investing with features that include: a fundamentals-based portfolio, weekly analysis on insights from institutional investors, regular alerts for short-term trade ideas based on technical signals, ticker feedback by request ...

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's (PFE) board of directors to take action against the latter’s management for making poor capital allocation, research and development (R&D) failures and problems with forecasting and budgeting.Per Starboard, these decisions have resulted in Pfizer losing nearly $20-$60 billion of market value since 2019, despite receiving a $40 billion boost from its COVID-19 franchise during the pandemic.This is the first time that ...

Pfizer Inc. (PFE) announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease. Following the latest FDA nod, Abrysvo has become the first and only RSV vaccine approved for adults who are younger than 50 years. Abrysvo is currently approved for t ...

Pfizer (PFE) will report its third-quarter 2024 earnings on Oct. 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.19 billion and 64 cents per share, respectively. Pfizer’s 2024 earnings estimates have risen from $2.62 to $2.66 per share over the past 30 days. For 2025, earnings estimates have been stable at $2.85 per share over the same timeframe.PFE Estimate MovementImage Source: Zacks Investment ResearchPFE’s Earnings Surprise HistoryThe healthcare bellwether’s ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.Pharmaceutical giant Pfizer (PFE -0.31%) has long been a player in the healthcare industry, but it's currently experiencing a bit of a hangover. Pfizer's business rapidly expanded during the COVID-19 pandemic, thanks to a temporary growth spurt from selling Comirnaty (its COVID-19 vaccine) and Paxlovid (its antiviral therapy for COVID-19).But those sales have fallen dramatically as pandemic pressur ...

Drug giant Pfizer (PFE) is trading quite cheap after its stock took a beating last year once the pandemic ended. The stock is trading at a discount to the industry and is also trading below its 5-year mean. Going by the price/earnings ratio, the company's shares are currently trading at 10.25 forward earnings, lower than 19.08 for the industry and the stock’s 5-year mean of 11.37.Image Source: Zacks Investment ResearchIf you consider the price/sales ratio, its forward sales multiple of 2.63 is lower than it ...

Activist investor Starboard Value has sharpened its criticism of Pfizer Inc. PFE, holding the pharmaceutical giant’s management accountable for failing to deliver on its promises of innovation and growth.Despite its relatively small stake in Pfizer, Starboard’s critique reflects broader investor frustration with the company’s stock, which has dropped about 50% since 2021.During the Active-Passive Investor Summit, Starboard argued that Pfizer’s leadership, under CEO Albert Bourla, has not fully capitalized o ...